Nuvation Bio to Present at the Cantor Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Cantor Global Healthcare Conference in New York, NY on Thursday, September 19, 2024, at 9:45 a.m. E.T.

A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.

About Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com and https://www.linkedin.com/company/nuvationbio/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240909328377/en/

Nuvation Bio Investor Contact:
[email protected]

Nuvation Bio Media Contact:
[email protected]

Source: Nuvation Bio

You May Also Be Interested In

• Rönesans Selects MEVION S250-FIT for Landmark Proton Therapy Investment in Türkiye
• Ledyard Financial group to Present at the Financial Services Virtual Investor Conference September 24th
• New 3Sixty Insights Analysis Reinforces the Importance of Insperity's HRScale Service-Enabled HR Solution